Cigna CEO granted options, 3,113 restricted shares

Cigna Group CEO Brian C. Evanko received new option and restricted stock awards, increasing his direct and indirect equity holdings.

Rhea-AI Filing Summary

Cigna Group (CI) reports that President and Chief Executive Officer Brian C. Evanko received equity awards on September 1, 2026. He was granted 6,716 stock options with an exercise price of $281.1325 per share and a separate award of 3,113 restricted shares, both vesting in three equal annual installments beginning September 1, 2027. Following these grants, he holds 41,030 common shares directly, plus indirect holdings of 25,614 shares through a GRAT and 919.5791 shares through Cigna’s 401(k) Plan. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 9,829 shares

Grant/Award 4 txns

Insider Evanko Brian C

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F3	6,716	$0.00	$0.00
Grant/Award	Common Stock, $.01 Par Value F1	3,113	$0.00	$0.00
holding	Common Stock, $.01 Par Value	--	--	--
holding	Common Stock, $.01 Par Value F2	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 6,716 contracts (Direct); Common Stock, $.01 Par Value — 41,030 shares (Direct); Common Stock, $.01 Par Value — 25,614 shares (Indirect, By GRAT); Common Stock, $.01 Par Value — 919.5791 shares (Indirect, By 401(k))

Footnotes (3)

1. F1. These restricted shares vest in three equal annual installments beginning September 1, 2027.
2. F2. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
3. F3. This option vests in three equal annual installments beginning September 1, 2027.

Key Figures

Stock options granted: 6,716 options Option exercise price: $281.1325 per share Restricted shares granted: 3,113 shares +5 more

8 metrics

Stock options granted 6,716 options Employee stock options granted to Brian C. Evanko on September 1, 2026

Option exercise price $281.1325 per share Exercise price for 6,716 employee stock options granted on September 1, 2026

Restricted shares granted 3,113 shares Restricted common shares granted on September 1, 2026, vesting over three years

Direct common shares after transaction 41,030 shares Direct Cigna Group common stock holdings of Brian C. Evanko after the grants

Indirect GRAT holdings 25,614 shares Cigna Group common stock held indirectly by GRAT associated with Brian C. Evanko

Indirect 401(k) holdings 919.5791 shares Cigna Group common stock held indirectly through The Cigna Group's 401(k) Plan

Option expiration date September 1, 2037 Expiration date of the 6,716 employee stock options granted

Vesting commencement September 1, 2027 Start date for three-year vesting of both restricted shares and options

Key Terms

Employee Stock Option, restricted shares, 401(k) Plan, GRAT

4 terms

Employee Stock Option financial

"Security titled "Employee Stock Option (Right to Buy)" was granted"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

restricted shares financial

"These restricted shares vest in three equal annual installments"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

401(k) Plan financial

"Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

GRAT financial

"Indirect ownership noted as "By GRAT" for certain holdings"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Cigna Group (CI) grant to Brian C. Evanko on September 1, 2026?

On September 1, 2026, Brian C. Evanko was granted 6,716 stock options with a $281.1325 exercise price and 3,113 restricted shares of Cigna Group common stock, both vesting in three equal annual installments beginning September 1, 2027.

How many Cigna Group (CI) shares does Brian C. Evanko hold directly after these transactions?

After the September 1, 2026 grants, Brian C. Evanko directly holds 41,030 shares of Cigna Group common stock, according to the Form 4 filing.

What indirect Cigna Group (CI) holdings are reported for Brian C. Evanko?

Indirectly, Brian C. Evanko is reported to hold 25,614 Cigna Group shares through a GRAT and 919.5791 shares through The Cigna Group’s 401(k) Plan, as of the September 1, 2026 Form 4.

When do Brian C. Evanko’s new Cigna (CI) restricted shares vest?

The 3,113 restricted shares granted to Brian C. Evanko vest in three equal annual installments beginning September 1, 2027, according to the footnote on the Form 4.

What is the vesting schedule for Brian C. Evanko’s new Cigna (CI) stock options?

The 6,716 stock options granted to Brian C. Evanko vest in three equal annual installments beginning September 1, 2027, and are exercisable at $281.1325 per share until their expiration on September 1, 2037.

Were Brian C. Evanko’s Cigna (CI) transactions under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is marked to indicate no Rule 10b5-1 trading plan for these September 1, 2026 equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:31 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evanko Brian C

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CONNECTICUT 06002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	09/01/2026		A		3,113(1)	A	$0	41,030	D
Common Stock, $.01 Par Value								25,614	I	By GRAT
Common Stock, $.01 Par Value								919.5791(2)	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$281.1325	09/01/2026		A		6,716		09/01/2027(3)	09/01/2037	Common Stock, $0.01 Par Value	6,716	$0	6,716	D

Explanation of Responses:

1. These restricted shares vest in three equal annual installments beginning September 1, 2027.

2. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

3. This option vests in three equal annual installments beginning September 1, 2027.

Remarks:

President and Chief Executive Officer

	Tyler Gratton, attorney-in-fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)